The top-five vaccine manufacturers within the country, on Monday, briefed the National Expert Group on Vaccine Administration about the event of COVID-19 vaccines in India. at the present , there are three COVID-19 vaccine candidates within the country.
Covaxin by Bharat Biotech and ZyCoVD by Zydus Cadilla are two home-grown COVID-19 vaccine candidates. Serum Institute of India has partnered with British Swedish firm AstraZeneca to manufacture the vaccine developed by University of Oxford. aside from these three firms, top executives of Biological E and Gennova Biopharmaceuticals also made presentation at the meeting.
The panel also discussed whether or not they need any help from the govt to build up production if their candidate vaccines are found safe and effective in clinical trials.
The expert group earlier discussed the creation of a digital infrastructure for inventory management and delivery mechanism of a coronavirus vaccine once it becomes available. It also discussed the procurement strategy for a COVID-19 vaccine.
The expert committee formed by the central government, includes Dr VK Paul, a member (health) at the NITI Aayog, AIIMS director Dr Randeep Guleria, representatives of the ministries of external affairs, biotechnology, information technology, the Director General of Health services, India’s Aids Research Institute, the Indian Council of Medical Research, and also representatives from states.
Prime Minister Narendra Modi on Saturday said, “When scientists will give us the green signal, it’ll be produced on a mass scale and every one preparations are made for it.”
“I want to inform people, the talent of our scientists is like that of ‘rishi munis’ and that they are working very hard in laboratories,” Modi added while addressing the state on Independence Day .
India with its “great diary in low cost drug manufacturing” will play a serious role against coronavirus, believes Nobelist Peter Charles Doherty. “Given India’s great diary in low cost drug and vaccine manufacture, we expect that India are going to be a serious player. This is, after all, the fastest thanks to return global economic activity,” said Doherty.
India’s first COVID-19 vaccine Covaxin has been developed by Bharat BioTech, Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV). Hyderabad-based vaccine maker has “successfully completed” Phase-I human clinical trials of the vaccine and Phase-II will start soon, Assam health minister Himanta Biswa Sarma said.
Another vaccine was developed by Zydus Cadila. Dubbed as ZyCoV-D, Zydus’ COVID-19 vaccine commenced phase II clinical trial clinical trials from Transfiguration . “ZyCoV-D was found to be safe and well tolerated within the clinical test |phase I|clinical trial|clinical test”> phase I clinical trial clinical trial,” the drug maker said.
“All the themes in clinical test |phase I|clinical trial|clinical test”> phase I clinical trial clinical trial were closely monitored during a clinical pharmacological unit for twenty-four hours post dosing for safety and for 7 days thereafter and therefore the vaccine was found to be very safe,” Zydus Cadila Chairman Pankaj R Patel said